The Curative Effect Research Of Inhaled Budesonide Combined With Formoterol On Moderate Or Severe Chronic Obstructive Pulmonary Disease Of Stabilization Period

Objectives To evaluate the influence of combination therapy of chronically inhaling budesonide and formoterol on lung function, health-related quality of life to patients and untoward reaction of drugs with moderate or severe chronic obstructive pulmonary disease (COPD) of stabilization period. Through contrasting with the other frequently used treatment methods to evaluate therapeutic efficacy and safety of combination therapy,And eventually finding a more reasonable long term treatment method for patients with moderate or severe COPD.Methods 67 ceses with moderate or severe COPD cases of stabilization period were randomly divided into control group and treatment group by a randomized,one-blind way. The control group was treated with praeparatum of theophylline species (aminophylline or doxofylline) by mouth and inhaled short-actingβ2-agonist (salbutamol aerosol,200μg,tid or terbutaline aerosol,500μg,tid); And the treatment group attached to inhaling budesonide/formoterol (the trade name is symbicort turbuhaler,160μg/4.5μg,bid) for 12 months.The index of lung function and the score of health-related quality of life (The St. George's Hospital Respiratory Questionnaire,SGRQ) and untoward reaction of drugs were observed respectively before and after 6 and 12 months'treatment to evaluate the curative effects and safety of the drugs.Result 30 ones of the 33 control group patients and 31 ones of the 34 treatment group patients had finished the therapy and follow-up visit.①The comparison of lung function indexes:Compared to pretherapy,the general averages'improvement of FEV1% prediction value ,FEV1/ FVC and PEF in treatment group had no statistically significance (P>0.05) after 6 months'treatment,and above-mentioned indexes all had been heightened after 12 months'treatment when the course of treatment completed,but the general averages'improvement of had no statistically significance (P>0.05);contrast with pretherapy, the indexes of FEV1% prediction value ,PEF and FEV1/FVC in the control group had been decreased after therapy ,and the difference had statistically significance (P<0.05) . Compared to the control group , group comparison indicated that the lung function indexes'degression of FEV1% prediction value,FEV1/FVC and PEF in treatment group all had obviously been delaied after 6 and 12 months'therapy ,the difference had statistically significance(P<0.05).②The comparison of the score of health-related quality of life:the differences of SGRQ between two groups had no statistically significance after 6 months'therapy(P>0.05),but the scores of each domain and total assessment in treatment group all less than the cases of the concurrent control group after 12 months'therapy,the difference had statistically significance(P<0.05).Compared to pretherapy,The SGRQ of each domain and total assessment in treatment group all had been descended after 6 months'therapy (P<0.05),the scores continuously decreased after 12 months'therapy,the difference had statistically significance(P<0.01);the indexes of respiration symptom and total assessment scores in the control group had been improved after 6 months'therapy,the difference had statistically significance(P<0.05),and the scores of each domain and total assessment had been furthermore improved after 12 months'therapy (P<0.05).③The comparison of two groups'untoward reaction had no statistically significance.Conclusion The combination therapy of chronically inhaling budesonide/formoterol can delay the lung function'degression and improve the health-related quality of life in moderate or severe COPD cases of stabilization period,and the curative effect has superior to the control group and untoward reaction hasn't been increased.The combination therapy of inhaled budesonide and formoterol is a safe and effective choice of long term reatment perscriptions to moderate or severe COPD cases of stabilization period.